Navigation Links
Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
Date:11/28/2012

GREENWOOD VILLAGE, Colo., Nov. 28, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (AMPE), a biopharmaceutical company developing repurposed drugs and new molecular entities (NMEs) that treat inflammatory diseases, including osteoarthritis, diabetic macular edema (DME) and sexual dysfunction announced the appointment of Josh Disbrow as Chief Operating Officer of Ampio Pharmaceuticals, effective December 15, 2012.

(Logo:  http://photos.prnewswire.com/prnh/20120516/MM09116LOGO)

Mr. Disbrow was most recently the Vice President of Commercial Operations at Arbor Pharmaceuticals. He joined Arbor in 2007 as the company's second full time employee and led the company's commercial efforts from inception to $127 million in annual sales in 2011 at which time the company was sold to an investor group. Since the company's acquisition, Josh remained with Arbor and oversaw the growth of the company's commercial infrastructure to over 150 people in sales, marketing, and other commercial functions. During his time at Arbor, Josh also served as the company's commercial lead on all business and corporate development activities including in-licensing, out-licensing, partnering, mergers and acquisitions, and university collaborations.

Arbor began as an entrepreneurial venture with no products on the market. Through Josh's leadership Arbor developed into a fully integrated specialty pharmaceutical company with a focus on bringing novel prescription pharmaceuticals to market through efficient product development, aggressive business development, corporate partnerships, and efficient commercial scale-up.

Mr. Disbrow has spent 17 years in the pharmaceutical, diagnostic, and medical device industries and has held positions of increasing responsibility in sales, marketing, sales management, commercial operations, and commercial strategy.
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Champions Oncology Reports Financial Results for the Year Ended April 30, 2012
2. Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities
3. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
4. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
5. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
6. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
7. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
8. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
9. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
10. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
11. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... USA (PRWEB) November 26, 2014 Biomedical ... accuracy, additive systems to enable 3D manufacture at the ... road conditions are among finalists in nine categories for ... The awards are sponsored by SPIE, the international ... Media . , Winners will be announced by industry ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 2014 ... is a professional and in-depth research report on ... information, like its definition, classification, application, and industry ... report covers the international market analysis, including China’s ... the US, Europe, Asia, China, Japan etc. regions) ...
(Date:11/26/2014)... YORK , Nov. 26, 2014 The ... may indicate the company is looking to expand in ... further sales.  The healthcare market research firm says that  ... to Kalorama Information,s biennial survey of the IVD market ... and any change in its composition would likely affect ...
(Date:11/26/2014)... November 26, 2014 On January, 14, ... Baltimore and Washington D.C. science community to the UMBC ... event, sponsored by the Protein Society, will take place ... Center, Room 312. Through discussion, presentations and workshops, ... importance of proteins, their role in the industry and ...
Breaking Biology Technology:Finalists Named for 2015 Prism Awards for Photonics Innovation 2Finalists Named for 2015 Prism Awards for Photonics Innovation 3Finalists Named for 2015 Prism Awards for Photonics Innovation 4Finalists Named for 2015 Prism Awards for Photonics Innovation 5Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 2Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 3Kalorama: Sale of Three Siemens Healthcare Units Raises Questions About Firm's IVD Future 2
... Continuous Enhancement Model and Customer Advisory Board Programs ... Service Leader in Talent Management Market, OTTAWA, ... leading,provider of web-based employee performance and talent management ... valuable insight,into real-life HR issues and challenges and ...
... Three Hospitals in Western Pennsylvania Earn Designation, ... Shield,has named Allegheny General Hospital, UPMC Presbyterian Shadyside ... and Rare Cancers., Complex and rare cancers ... year, making it difficult for patients to locate ...
... March 11 Cardium Therapeutics,(Amex: CXM ) ... by researchers at Emory University, which demonstrated highly,efficient ... muscle lacking sufficient blood flow as a result ... an occlusion and reperfusion model,analogous to a heart ...
Cached Biology Technology:Halogen Customers Shape Industry-Leading Employee Performance and Talent Management Solution 2Halogen Customers Shape Industry-Leading Employee Performance and Talent Management Solution 3Highmark Blue Cross Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers 2Highmark Blue Cross Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers 3Cardium's Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion 2Cardium's Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion 3Cardium's Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion 4Cardium's Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion 5Cardium's Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion 6Cardium's Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion 7
(Date:11/4/2014)... amount of death at the right time might actually ... research that could help in understanding animal populations, pest ... a paper in the journal Trends in Ecology ... colleagues conclude that the kind of positive population effect ... or mortality, depends on the size and developmental stage ...
(Date:11/4/2014)...   3D scanner ... Fuel3D , a developer of 3D scanning solutions, ... $6.4 million (£4 million). This funding builds on the company,s ... and paves the way for the commercial launch of the ... round was led by Chimera Partners and will be used ...
(Date:11/3/2014)... of Colorado Cancer Center study published in ... Sciences describes the activity of a recently discovered ... or IL-37. It has been known to limit inflammation ... adaptive immune system: IL-37 inhibits the ability of the ... "Knowing this mechanism that underlies IL-37,s effect on the ...
Breaking Biology News(10 mins):When less is more: Death in moderation boosts population density in nature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3PNAS: From HIV to cancer, IL-37 regulates immune system 2
... a link between massive volcanic eruptions along the east coast ... million years ago and a period of global warming that ... tropics and more than six degrees in the Arctic. , ... , The study is important, experts say, because it ...
... 243 acres in an East Tennessee valley adjacent to ... toxic waste from weapons manufacturing at the facility between ... radioactive plumes for miles from the contaminated site. ... Kostka and his FSU oceanography department team will help ...
... a decade’s worth of statistics, researchers are sounding a new ... men. , The overall number of syphilis cases in the ... in 2003 perhaps because of a nationwide prevention campaign aimed ... significantly in this decade. , "The entire nation ...
Cached Biology News:Volcanic eruptions, ancient global warming linked 2Volcanic eruptions, ancient global warming linked 3'Hidden-hero' microbes in soil, water may help naturally clean toxic sites 2Syphilis rate on rise in US gay, bisexual men 2
... Blasticidin is a nucleoside ... It is a potent ... prokaryotic and eukaryotic cells. ... conferred by the products ...
... Polyclonal Antibody against Aph-1a (Aph-1aL,S Loop ... gamma secretase is a multiprotein complex ... Pen-2; all four proteins are necessary ... secretase complex catalyzes cleavage of a ...
... are a group of enzymes important in ... mammals. The enzymes protect cells against toxicants ... glutathione to electrophilic xenobiotics, and thereby defend ... effects of the compounds. GST activity is ...
15(S)-HEDE is produced from 11Z,14Z-eicosadienoic acid by 15-LO. 15(S)-HEDE is an inhibitor of RBL-1 cell 5-LO with an IC50 value of 26 µM....
Biology Products: